Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein

Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein-bound is a phase 3, randomised interventional study registered as NCT07716228 by Second Affiliated Hospital, Zhejiang University, School of Medicine, with a registry enrolment figure of 74 participants, started 2025-12-12 and due to reach its primary completion in 2026-12-06. Interventions recorded: Auricular point stimulation plus dexamethasone; Standard pharmacologic antiemetic regimen. Conditions listed: Nausea and Vomiting Caused by Chemotherapy. Primary outcome: Proportion of patients experiencing nausea as assessed by NIC-CTC AE4.0. Pancreatic eligibility wording from the registry: "* Patients must meet the following inclusion criteria for the study: \* Age ≥ 18 years and ≤ 85 years; \* Patients with pancreatic cancer after radical resection or with advanced pancreatic cancer, who require further chemotherapy with the gemcitabine plus paclitaxel albumin-bound regimen; \* ECOG p". Sites: China. No results are recorded here; the registry entry is the source.